Nitric Oxide and Peroxynitrite Production in Ocular Inflammation

Janice Benson Allen,¹ Teresa Keng,² and Christopher Privalle²

¹College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina; ²Apex Bioscience, Inc., Research Triangle Park, North Carolina

Recent studies have implicated nitric oxide and peroxynitrite in the pathogenesis of many diseases, such as septic shock, arthritis, lung disease, and atherosclerosis. Nitric oxide (NO) exerts many diverse effects on vascular tone, affecting neurotransmission and cellular cytotoxicity/communication. Our laboratory and others have documented a proinflammatory role for NO in ocular inflammation. Uveitis, which is an inflammation of the highly vascular uveal tract in the eye, is a debilitating condition that can lead to visual impairment and blindness. It is characterized by acute, recurrent, or persistent inflammation with disruption of the blood-aqueous barrier and is accompanied by protein leakage and leukocyte infiltration into the aqueous humor and anterior chamber. Systemic injection of endotoxin into mice and rats, or intraocular injection of endotoxin into mice, rats, and rabbits induces acute uveitis, which clinically and histologically resembles acute anterior uveitis in humans. These models facilitate the study of pathogenic mechanisms that contribute to ocular inflammation. In addition to NO, superoxide anion radicals (O₂⁻), and peroxynitrite (ONOO⁻), the products of the reaction between NO and O₂⁻, are also implicated in uveitis. The role of peroxynitrite in ocular inflammation is still largely unknown. Characterization of the roles of these important uveitic mediators in the ocular inflammatory response will provide information critical to the understanding of the pathogenesis of intraocular inflammation so that more effective therapeutic intervention(s) can be developed.

— Environ Health Perspect 106(Suppl 5):1145–1149 (1998). http://ehpnet1.niehs.nih.gov/docs/1998/Supp-5/1145-1149allen/abstract.html

Key words: nitric oxide, peroxynitrite, uveitis, SIN-1, SOD, inflammation, NOS inhibitors

Introduction

Intense research has focused on the role of nitric oxide (NO) and peroxynitrite (ONOO⁻) in physiologic and pathophysiologic processes. NO is beneficial and necessary for normal physiologic processes such as vasodilation (1), platelet functions (2), and neurotransmission (3,4). In contrast, higher concentrations of NO are thought to be cytotoxic and may contribute to cell injury or inflammation in many disease states such as arthritis (5), lung disease (6), and atherosclerosis (7). The detrimental toxic effects of NO may be due to the formation of ONOO⁻ from the reaction between NO and superoxide anion radical (O₂⁻). Recent studies suggest that ONOO⁻ may also have both beneficial and detrimental effects (8).

The role of NO in the eye has been extensively investigated. The contribution of this regulatory molecule to ocular physiology is emerging, but additional attention must be directed toward the understanding of the pathalogy of eye diseases. To this end, animal models of uveitis have been extensively used to try to elucidate the complex cascade of events leading to uveitis. Uveitis involves the recruitment of leukocytes into the uvea and the disruption of the blood barrier, resulting in protein extravasation and cellular infiltration into the aqueous humor and anterior chamber (9,10). Studies from animal models of uveitis and human patients with uveitis implicate reactive oxygen/nitrogen radicals in this inflammatory process. In the studies detailed below, the importance of the reactive radicals in the initiation and development of ocular inflammation will be discussed.

Nitric Oxide

Nitric oxide is a small, membrane-permeable free radical synthesized from the terminal guanidino nitrogen of L-arginine by the enzyme NO synthase (NOS) (11). NOS exists in three isoforms and is differentially expressed in many different cell types (12,13). The different isoforms are transcribed from three distinct genes and catalyze the oxidation of L-arginine to L-citrulline (14,15). Required cofactors include NADPH, flavin adenine dinucleotide, flavin mononucleotide, calmodulin, heme, and tetrahydrobiopterin. The three NOS isoforms differ in calcium dependence, tissue distribution, amino acid sequence, regulation of expression, and function (16).

Endothelial NOS (eNOS or NOS3; 135 kDa) and neuronal NOS (nNOS or NOS1; 150–160 kDa) are constitutively expressed, require calcium, and are collectively referred to as constitutive NOS (cNOS) (3,17,18). Small amounts of NO are produced by these enzymes. NO generated from the eNOS pathway activates soluble guanylyl cyclase to produce the intracellular signaling molecule cGMP, which functions to relax vascular smooth muscle cells by decreasing intracellular calcium (18,19). NO produced by nNOS functions as a neurotransmitter in the nervous system (3,4).

A third isoform, an inducible NOS (iNOS or NOS2; 130 kDa), usually does not exist under normal conditions and is expressed in response to certain cytokines.
(interleukin [IL]-1β, tumor necrosis factor [TNF-α] and bacterial products [lipopolysaccharide [LPS]]) (13,20,21). Many cell types have the capacity to express iNOS after exposure to certain immunologic or inflammatory stimuli (22–29). High concentrations of ‘NO generated by this pathway are sustained for prolonged periods of time in vitro and in vivo (13,30). iNOS expression is delayed 2 to 8 hr after exposure to inducing cytokines; the delay is necessitated by the synthesis of essential cofactors (31). Elevated levels of ‘NO generated by the iNOS are thought to be involved in many inflammatory conditions (32–35).

The production of ‘NO can be inhibited by analogs of L-arginine, which compete with L-arginine for the active site of NOS (12,36–38). Nonamino acid compounds also inhibit NOS activity (39). Furthermore, inhibition of ‘NO can be achieved by limiting necessary cofactors of NOS activity and inhibiting signal transduction and transcription of NOS (39). NOS inhibitors exhibit different specificities for the NOS isoforms (22,39). For example, aminoguanidine (AG) is a more selective iNOS inhibitor (40,41) and N⁴-monomethyl-L-arginine and N⁴-nitro-L-arginine methyl ester (L-NAME) inhibit both cNOS and iNOS (22). More selective NOS inhibitors are needed to dissect the involvement of the different NOS isoforms in both physiologic and pathophysiologic processes.

**Peroxynitrite**

Peroxynitrite is a potent oxidant that is generated from ‘NO and O₂⁻ (42). Under pathologic conditions such as ischemia–reperfusion injury, inflammation, and sepsis, elevated levels of both ‘NO and O₂⁻ are produced by tissues. Because O₂⁻ reacts with ‘NO at a faster rate than with superoxide dismutase (SOD), a scavenger of O₂⁻, ONOO⁻ may be formed at high yields and contribute to the pathology. ONOO⁻ is also implicated in the pathogenesis of rheumatoid arthritis, shock associated with endotoxemia, silica–induced lung injury, neurotoxicity, endothelial injury, and colonic inflammation (43–45). ONOO⁻ directly and rapidly oxidizes sulfhydryl groups and initiates lipid peroxidation (46). Alternatively, ONOO⁻ can nitrate phenolic rings of tyrosine residues of proteins, leading to the formation of nitrotyrosine, which is easily detected with antinitrotyrosine antibodies (47). Thus, the presence of nitrotyrosine can serve as a ONOO⁻ “footprint.”

Just as is the case for ‘NO, other studies suggest that ONOO⁻ can mediate physiologic processes that are beneficial. ONOO⁻ produces vascular relaxation in isolated coronary (48) and pulmonary arteries (49). It also inhibits platelet aggregation (50). An important study by Lefer et al. (8) provides evidence that ONOO⁻, at nanomolar concentrations, significantly inhibits leukocyte–endothelial interactions both in vitro and in vivo by inhibiting the upregulation of P-selectin. In addition, the study showed that polymorphonuclear accumulation in ischemic–reperfused rat hearts was reduced by nanomolar concentrations of ONOO⁻. The differences in beneficial versus detrimental effects of ONOO⁻ may be, at least in part, concentration dependent, and underscore the complex biochemistry of ‘NO and ONOO⁻.

**‘NO and ONOO⁻ in the Eye**

The function of ‘NO in the eye has been extensively studied, from physiologic and pathophysiologic functions to therapeutic potential (51). All three NOS isoforms have been identified in different parts of the eye, either with NADPH-diaphorase staining or specific anti-NOS antibodies. There are multiple sites of action for the signaling properties of ‘NO produced by NOS1 and 3 isoforms. These NOS isoforms have been detected in the retina and in vascular endothelium of the anterior segment and choroid, in conjunctiva, and in ciliary muscle and trabecular meshwork. This suggests a therapeutic potential for the use of ‘NO donors (nitrovasodilators) in controlling retinal blood flow, aqueous humor dynamics, and regulation of intraocular pressure.

Behar-Cohen et al. (52) evaluated the effect of intraocular administration of ‘NO donors in the rabbit eye and observed a drastic decrease in intraocular pressure, with no inflammatory or toxic effects on ocular tissues. The NOS2 isoform produces larger amounts of NO, which contributes to cytotoxicity, and has been identified in the retina (pigmented epithelium, pericytes, and Muller cells) and iris–ciliary body. During uveitis, infiltrating polymorphonuclear and mononuclear cells express NOS2, probably after stimulation by uveitic cytokines such as IL-1β and TNF-α.

In an experimental guinea pig model of allergic conjunctivitis, ‘NO was shown to mediate increased conjunctival blood flow and hyperpermeability of sensitized guinea pigs after exposure to the antigen (48 of 80), or to histamine. Increased levels of nitrite were detected in lavage fluid 30 min after challenge, along with conjunctivitis, edema formation, and hyperpermeability. These inflammatory parameters were inhibited with pretreatment with L-NAME or AG (53,54). Neurotoxicity of NO in the retina was investigated in rabbits by intravitreal injection of the ‘NO donor S-nitroso- N-acetylpenicillamine (55). Retinal toxicity of ‘NO was shown both functionally and histologically, suggesting that ‘NO may play a role in retinal ischemia or in degenerative diseases. As in other physiologic and pathologic situations, the protective and detrimental effects of ‘NO and ONOO⁻ are complex and require further investigation. The ability of ‘NO and ONOO⁻ to lower intraocular pressure and increase retinal blood flow suggests a beneficial use in treatment of certain ocular situations such as glaucoma, but the potential retinal toxicity associated with increased ‘NO should be considered and investigated further.

**‘NO and ONOO⁻ in Experimental Uveitis**

In an experimental autoimmune uveitis model, Wu et al. (56) demonstrated ONOO⁻ formation in the photoreceptors, and to a lesser extent in the ganglion cell layers, nerve fiber cell layers, and blood vessels of the retina. These sites of ONOO⁻ production appear to correlate with the area of pathologic oxidation and may be a major factor in the degeneration of photoreceptors in this model.

Several investigations using the endotoxin-induced uveitis (EIU) mouse and rat models document the importance of ‘NO in ocular inflammation (57–65). Intraperitoneal injections of L-NAME, an inhibitor of both cNOS and iNOS, significantly decrease aqueous protein and cell numbers in the anterior chamber of EIU in rats (60). Tilton et al. (59) used the more specific iNOS inhibitor AG and demonstrated that the hemodynamic and vascular changes associated with EIU are in part due to increased ‘NO production. Others have shown increased iNOS mRNA in the iris–ciliary body in EIU by reverse transcriptase–polymerase chain reaction (64) and in situ hybridization (66). These studies conclude that ‘NO is an important mediator of uveitis and that inhibition of NOS decreases ocular inflammation.

The EIU model in rabbits is clinically and histopathologically similar to acute
antior uveitis in humans (9,10). The acute inflammation is associated with vascular and permeability changes in the anterior chamber of the eye. Studies of the pathogenesis of uveitis from human uveitis and animal models of ocular inflammation have identified increased cytokine (IL-1β, TNF-α, and IL-6) levels in uveitic ocular fluids and tissues compared to normal fluids and tissues (67–69). In addition, prostaglandins and other mediators have been associated with uveitis. Studies using the EIU model in rabbits have documented a role for ‘NO and ONOO−’ in ocular inflammation (65,70).

Endotoxin-induced uveitis in rabbits is induced by a single intravitreal injection of endotoxin (10 ng; *Escherichia coli*) into one eye of New Zealand white male rabbits (2–3 kg) and the appropriate vehicle into the contralateral eye (9,10). Temporal assessment of uveitis is monitored by direct examination of the anterior segment with a slit-lamp biomicroscope. Evidence of disruption of ocular barriers (protein exudation; ‘aqueous flare’) is graded from 0 to 4, with 0 being normal and 4 being maximal light diffraction (71). Iridal hyperemia, a measure of iridal blood vessel dilation in the iris–ciliary body in addition to aqueous flare, is also graded (0–4). These more subjective observations are quantitated at the termination of the experiment by measuring aqueous protein levels and counting the number of aqueous inflammatory cells (9,10). The eyes are removed and processed for histologic/molecular analyses. Hematoxylin and eosin-stained sections of eye, removed 18 to 24 hr after endotoxin injection, show a predominantly polymorphonuclear infiltrate with some mononuclear cells and a proteinaceous exudate in the anterior chamber. Animals are used in accordance with the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Research and approved by the North Carolina State University Institutional Animal Care and Use Committee.

In an attempt to dissect the importance and contribution of the different NOS isoforms in uveitis, the authors used the iNOS and cNOS (L-NAME; 100 mM and 10 mM) and iNOS (AG; 114 mM) inhibitors in EIU in rabbits (65). These and additional published studies underscore the importance of determining which NOS isoform(s) is important at various stages of the inflammatory process. Rabbits were intravitreally injected in one eye with endotoxin (10 ng) with and without inhibitor and with endotoxin-free saline (vehicle) in the contralateral eye. Uveitis in rabbits coincident with endotoxin and L-NAMe was almost completely abolished in a dose-dependent manner, whereas co-injection of endotoxin and D-NAMe, N6-nitro-D-arginine methanelester, the inactive enantiomer, did not suppress uveitis. Co-injection of endotoxin and AG, a more selective inhibitor of iNOS, significantly suppressed all parameters of EIU and suggested the importance of iNOS in ocular inflammation. To determine if NOS inhibitors have an effect on established uveitis, L-NAMe was injected 0.5 hr and 6 hr after endotoxin administration. L-NAME still inhibited uveitis when injected 0.5 hr after endotoxin. However, injection of L-NAMe 6 hr after endotoxin actually exacerbated the inflammatory response. In contrast, injection of AG 6 hr after LPS did inhibit cellular infiltration and protein extravasation. Thus, the differential effects of NOS inhibitors with different specificities underscore the importance of the time of their administration in ameliorating ocular inflammation, and could have significant impact on our understanding of uveitis and possible therapeutic intervention.

Because O2−, which reacts with ‘NO to form ONOO−, also plays a role in intraocular inflammation (72), we examined aqueous humor proteins for evidence of ONOO− formation by examining protein nitration using immunoblot analysis (47). Several immunoreactive bands were observed in the EIU aqueous humors, compared to a decreased number of bands of immunoreactivity in vehicle-injected aqueous humors. The immunoreactivity was eliminated by co-incubation of antibody with 10 mM nitrotyrosine. In addition, aqueous humors from eyes co-injected with inhibitors of NOS contained decreased levels of immunoreactivity. Sections of iris–ciliary processes from inflamed eyes stained with anti-nitrotyrosine antibody showed positive staining, primarily in the cellular infiltrate. Taken together, these results suggest that ONOO− may also be involved in uveitis. Thus, by inhibiting the formation of ‘NO, formation of the tissue-damaging ONOO− would also be reduced, and intraocular inflammation is attenuated. Additional studies to assess the potential direct inflammatory effects of ONOO− in the eye were performed (73). Rabbits were injected intravitreally every 3 hr for 15 hr with 3-morpholininosydnonimine hydrochloride (SIN-1) (5 mM), which donates ‘NO and O2− simultaneously and therefore ONOO− or SIN-1 + SOD (10 mM); contralateral eyes received the same volume and number of injections of vehicle. Coinjection of an excess of the O2− scavenger SOD with SIN-1 results in only ‘NO formation and allows intravitreal effects of ‘NO and ONOO− to be independently evaluated. Eighteen hours after injection, rabbits injected with SIN-1 developed moderate iridal vasodilation and disruption of the blood–aqueous barrier, with some cellular infiltration into the aqueous humor. SIN-1 + SOD− and vehicle-injected rabbits did not exhibit significant responses. These results suggest a direct role for ONOO− in uveitis. Characterization of these important uveitic mediators in the ocular inflammatory response will provide information critical to understanding the pathogenesis of intraocular inflammation.

Conclusions

Administration of NOS inhibitors with different isoform specificities at the onset or during EIU exerts differential effects on this inflammatory response, indicating that ‘NO is an important mediator of uveitis. We have demonstrated evidence of ONOO− formation in uveitic ocular fluids, and that ONOO− exhibits direct inflammatory effects in the eye. The studies described above underscore the importance of ‘NO and ONOO− in ocular physiology and pathophysiology. Development of even more selective NOS inhibitors will be necessary in order to distinguish the involvement of the different NOS isoforms, thus allowing for control of harmful, induced ‘NO production, while not affecting the physiologic actions of constitutive ‘NO release.

REFERENCES AND NOTES

1. Furchtgott RF, Zawodzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373–376 (1980).

2. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregation properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92:639–646 (1987).

3. Snyder SH. Nitric oxide: first in a new class of neurotransmitters. Science 257:494–496 (1992).
4. Bret D, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 86:9030–9033 (1989).

5. Evans CH, Stefanovic-Racic M. Nitric oxide in arthritis. Methods 10:38–42 (1996).

6. Laskin JD, Heck DE, Laskin DL. Multifunctional role of nitric oxide in inflammation. TEM 5:377–382 (1994).

7. Matthys KE, Bult H. Nitric oxide function in atherosclerosis. Med Inflamm 6:3–21 (1997).

8. Lefer DJ, Scalari R, Campbell B, Nosuli T, Hayward R, Salamon M, Grayson J, Lefer AM. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. Lab Clin Invest 96:684–689 (1997).

9. Fleisher LN, Ferrell JB, McGahan MC. Occluded inflammatory effects of intraventricular-injected tumor necrosis factor-alpha and endothotoxin. Inflammation 14:325–335 (1990).

10. Allen JB, McGahan MC, Ogawa Y, Sellon DC, Clark BD, Fleisher LN. Intravitreal transforming growth factor-B2 decreases cellular infiltration in endotoxin-induced ocular inflammation in rabbits. Curr Eye Res 15:95–103 (1996).

11. Martella MA. Nitric oxide synthase structure and mechanism. J Biol Chem 268:12231–12234 (1993).

12. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142 (1991).

13. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051–3064 (1992).

14. Steuhr DJ, Hwang PM, O'Boyle RJ. Tetrahydrobiopterin-independent nitric oxide synthases. Adv Enzymol Mol Relat 65:287–346 (1992).

15. Nathan C, Xie Q-W. Nitric oxide synthases: roles, tolls, and controls. Cell 78:915–918 (1994).

16. Nathan C, Xie Q-W. Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725–13728 (1994).

17. Gibaldi M. What is nitric oxide and why are so many people studying it? J Clin Pharmacol 33:489–496 (1993).

18. Bret D, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structure resembles cytochrome P-450 reductase. Nature 351:714–718 (1991).

19. Pollock JS, Forstermann JA, Mitchell TD, Warner HHHW, Schmidt HH, Nakane M, Murad F. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA 86:3469–3473 (1989).

20. Lorsbach RB, Murphy WJ, Lowenstein CJ, Snyder SH, Russell SW. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. J Biol Chem 268:1908–1913 (1993).

21. Billiar TR, Curran RD, Ferrari FK, Williams DL, Simmons RL. Kupffer cell/hepatocyte cocultures release nitric oxide in response to bacterial endotoxin. J Surg Res 48:349–353 (1990).

22. Hibbs JB Jr, Taintor RR, Varnin Z. Macrophage cytotoxicity: role of L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235:473–476 (1987).

23. Steuhr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing l-arginine-specific NO synthase. Proc Natl Acad Sci USA 88:7777–7777 (1991).

24. Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease. NY Acad Sci 664:103–115 (1992).

25. McCall TB, Boughton-Smith NK, Palmer RMJ, Whittle BJR, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Biochem J 261:293–296 (1989).

26. Curran RD, Billiar TR, Steuhr DJ, Hoffman K, Simmons RL. Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products from Kupffer cells. J Exp Med 170:1769–1774 (1989).

27. Schule R, Nava E, Moncada S. Induction and possible biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105:577–580 (1992).

28. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reinegger G, Trentz O. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med 172:1599–1607 (1990).

29. Beasley D, Schwartz JH, Brenner BM. Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 87:602–608 (1991).

30. Nuessler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leuk Biol 54:171–178 (1993).

31. Morris Jr, SM, Billiar TR. New insights into the regulation of inducible nitric oxide synthase. Am Physiol Soc 94:E829–E839 (1994).

32. Anon. Nitric oxide in the clinical arena. Lancet 338:1560–1562 (1991).

33. Billiar TM, Hoffman RA, Curran RD, Langerei JM, Simmons RL. A role for inducible nitric oxide biosynthesis in the liver in inflammation and in the allogeneic immune response. J Lab Clin Med 120:192–197 (1992).

34. Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated septic shock. J Natl Cancer Institute 84:827–831 (1992).

35. Nava E, Palmer RMJ, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 338:1555–1557 (1991).

36. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329:2002–2012 (1993).

37. Hasan K, Hessein BJ, Corbett JA, McDaniel ML, Chang K, Allison W, Wolffenbuttel BHR, Williamson JR, Tilton RG. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 249:101–106 (1993).

38. Rees DD, Palmer RMJ, Schultz R, Hudson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746–752 (1990).

39. Tilton RG. Role of nitric oxide in vascular dysfunction associated with ocular disease. In: Advances in Ocular Toxicology (Green K, Edelhauser HF, Hacker RB, Hull DS, Potter DE, Tripathi RD, eds.). New York:Plenum Press, 1997:133–149.

40. Misko TP, Moore WM, Katten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel M, Williamson JR, Currie MG. Selective inhibition of the inducible nitric oxide synthase activity of aminoguanidine. Eur J Pharmacol 233:119–125 (1993).

41. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine is a potent inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 93:2684–2690 (1994).

42. Beckman JS, Beckman TW, Chen J, Marshall PM, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620–1624 (1990).

43. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 233:229–240 (1994).

44. Darley-Usmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBs Lett 369:131–135 (1995).

45. Pryor WA, Padmaja S. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268:L699–L722 (1995).

46. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288:484–487 (1991).

47. Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 298:446–451 (1992).

48. Liu S, Beckman JS, Ku DD. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J Pharmacol Exp Ther 268:1114–1121 (1994).

49. Wu MN, Prichard KA, Kaminski PM, Fayngers RP, Hintze TH, Wolin MS. Involvement of nitric oxide and nitrosothiols in relaxation of pulmonary arteries to peroxynitrite. Am J Physiol 266:H2108–H2113 (1994).
50. Naseem KM, Bruckdorfer KR. Hydrogen peroxide at low concentrations strongly enhances the inhibitory effect of nitric oxide on platelets. Biochem J 310:149–153 (1995).
51. Beijler F, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. Surv Ophthalmol 42:71–82 (1997).
52. Behar-Cohen F, Goureau O, D’Hermies D, Courtois Y. Decreased intraocular pressure induced by nitric oxide is correlated to nitric production in the rabbit eye. Invest Ophthalmol Vis Sci 37:1711–1715 (1996).
53. Meijer F, Ruijter JM, Van Delft JL, Van Haeringer NJ. Nitric oxide induces vascular permeability changes in the guinea pig conjunctiva. Eur J Pharmacol 284:61–67 (1995).
54. Meijer F, Van Delft JL, Garrels IM, Van Haeringer NJ, Kijlstra A. Nitric oxide plays a role as a mediator of conjunctival edema in experimental allergic conjunctivitis. Exp Eye Res 62:359–365 (1996).
55. Oku H, Yamaguchi H, Sugiyama T, Kojima S, Ota M, Azuma I. Retinal toxicity of nitric oxide released by administration of a nitric oxide donor in the albino rabbit. Invest Ophthalmol Vis Sci 38:2540–2544 (1997).
56. Wu G-S, Zhang J, Rao NA. Peroxynitrite and oxidative damage in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 38:1333–1339 (1997).
57. Mandai M, Mittag T, Yoshimura N, Honda Y. Role of nitric oxide synthase isoforms in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 36:5546 (1995).
58. Mandai M, Yoshimura N, Yoshida M, Iwaki M, Honda Y. The role of nitric oxide synthase in endotoxin-induced uveitis: effects of Nω-nitro-L-arginine. Invest Ophthalmol Vis Sci 35:3673–3680 (1994).
59. Tilton RG, Chong K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 35:3278–3288 (1994).
60. Parks DJ, Cheung MK, Chan CC, Roberge FG. The role of nitric oxide in uveitis. Arch Ophthalmol 112:544–546 (1994).
61. Wang ZY, Hakanson R. Role of nitric oxide (NO) in ocular inflammation. Br J Pharmacol 116:2447–250 (1995).
62. Bellot J, Goureau O, Thillaye B, Chatenoud L, De Kozak Y. Inhibition of endotoxin-induced uveitis by nitric oxide (NO) synthase inhibitor; effect on intraocular TNF and NO synthesis. In: Advances in Ocular Immunology (Nussenblatt RB, Whitcup SM, Caspi RR, Gery I, eds). New York:Elsevier Science Publishers, 1994:225–228.
63. Bellot JL, Palmero M, Garcia-Cabanes C, Espi R, Hariton C, Orts A. Additive effect of nitric oxide and prostaglandin-E2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit. Inflamm Res 45:203–208 (1996).
64. Goureau O, Bellot J, Thillaye B, Courtois Y, de Kozak Y. Increased nitric oxide production in endotoxin-induced uveitis. Reduction of uveitis by an inhibitor of nitric oxide synthase. J Immunol 154:6518–6523 (1995).
65. Allen JB, McGahan MC, Ferrell JB, Adler KB, Fleisher LN. Nitric oxide synthase inhibitors exert differential time-dependent effects on LPS-induced uveitis. Exp Eye Res 62:21–28 (1996).
66. Jacquemin E, De Kozak Y, Thillaye B, Coutrois Y, Goureau O. Expression of inducible nitric oxide synthase in the eye from endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 37:1187–1196 (1996).
67. Davis JL, Jalkh AE, Roberge F, Caspi R, Flynn HW Jr, Scheepens CL, Nussenblatt RB. Subretinal fluid from human retinal detachment contains interleukin-1. Invest Ophthalmol Vis Sci 29:65 (1988).
68. Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Drummond DC. Cytokines in proliferative vitreoretinopathy. Eye 5:686–693 (1991).
69. Murray PI, Hoekzema R, Van Haren MAC, De Han FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci 31:917–920 (1990).
70. Allen JB, McGahan MC, Fleisher LN, Privalle CT. Intravitreal lipopolysaccharide (LPS) induces peroxynitrite formation. Invest Ophthalmol Vis Sci 37:5918 (1996).
71. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. I: Anterior uveitis. Am J Ophthalmol 47:155–170 (1959).
72. Sery TW, Pettrillo R. Superoxide anion radical as an indirect mediator in ocular inflammatory disease. Curr Eye Res 3:243–252 (1984).
73. Allen JB, Bond AL, Keng T, Privalle C. Intravitreal peroxynitrite donor administration induces ocular inflammation in rabbits. Invest Ophthalmol Vis Sci 38:5191 (1997).